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early and aggressive disease control and prevention of compli-
cations especially in those with renal involvement.
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Background and aims The management of lupus nephritis (LN)
has evolved over time. There is limited data on renal flares in
the recent era.
Methods We investigated the renal relapse rate in 139 patients
with a history of Class III/IV±V diagnosed during the period
of Jan 1983 to Dec 2013, and the factors associated with
renal flares.
Results 135 episodes of renal relapse occurred over 112.5
±88.4 months, giving a flare rate of 0.108 episode per
patient-year. Reduced risk of renal flare was associated with
maintenance treatment using mycophenolate (MPA) (OR
0.314, 95% CI 0.099–0.994, p=0.049), complete remission
after the prior episode of active LN (OR 0.329, 95% CI
0.133–0.810, p=0.016), and diagnosis of LN after 1998 (OR
0.305, 95% CI 0.133–0.700, p=0.005) when maintenance
therapy with MPA was instituted. Low-dose prednisolone and
MPA maintenance immunosuppression was associated with bet-
ter relapse-free survival (5 year 91% and 10 year 83%) than
prednisolone and azathioprine (AZA) (70% and
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52% respectively, p=0.044) (Figure 1). LN diagnosed in
1998–2013 was associated with 5 year and 10 year relapse-
free survival rates of 93% and 86% respectively, compared
with 81% and 66% respectively (p=0.017) for patients who
presented in 1983–1997 (Figure 2).
Conclusions The risk of renal relapse has decreased in the cur-
rent era, probably attributed to replacement of AZA with
MPA as maintenance treatment.
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Background and aims Pre-emptive immunosuppressive treat-
ment for asymptomatic serological activation (ASR) in lupus
nephritis (LN) patients remains controversial, and its impact
on subsequent flare rate and long-term renal outcome is
unclear.
Methods We conducted a retrospective study on all episodes
of ASR in 1993–2015 to investigate the relationship between
pre-emptive treatment and subsequent clinical flares and renal
outcomes.
Results 138 episodes of ASR occurred in 98 patients during
the study period. 53 episodes (in 38 patients) were treated
with pre-emptive increase in immunosuppression while 85 epi-
sodes (in 60 patients) were not, and patients were followed
up for 88.8±77.3 months and 82.8±89.7 months respectively
after ASR occurred. Pre-emptive treatment was associated with
superior renal relapse-free survival (100%, 95% and 90% at
6, 12 and 24 months respectively) compared with no pre-
emptive treatment (93%, 68% and 65% respectively,
p=0.007), while extra-renal relapse-free survival did not differ
between the two groups (Figure 1). 5 (9.4%) of 53 ASR epi-
sodes treated pre-emptively developed renal flare at 14.3±6.7
months after ASR. Patients who received pre-emptive treat-
ment for ASR and did not develop renal flares showed also
better eGFR slope (+0.54±0.43 ml/min/1.73 m2/year) com-
pared with the non-pre-emptive groups with or without renal
flares (2.11±0.50 and 1.00±0.33 ml/min/1.73 m2/year
respectively, p=0.001 and 0.012) (Figure 2). Pre-emptive treat-
ment was associated with more gastrointestinal adverse events
related to increased mycophenolate dose (p=0.031). Infection
rate was similar between both groups.
Conclusions Renal flares have a negative impact on renal func-
tion and pre-emptive treatment for ASR could reduce renal
flare risk and its consequences in LN patients.
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Abstract 424 Table 1 CVE in women with SLE born in Sweden between 1951-1971.
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